Another “String to the Bow” of PJ34, a Potent Poly(ADP-Ribose)Polymerase Inhibitor: An Antiplatelet Effect through P2Y12 Antagonism?
M Lechaftois, E Dreano, B Palmier, I Margaill… - Plos one, 2014 - journals.plos.org
Background Neuro-and vasoprotective effects of poly (ADP-ribose) polymerase (PARP)
inhibition have been largely documented in models of cerebral ischemia, particularly with …
inhibition have been largely documented in models of cerebral ischemia, particularly with …
Protective effects of PJ34, a novel, potent inhibitor of poly (ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke
GE Abdelkarim, K Gertz, C Harms… - International …, 2001 - spandidos-publications.com
Focal cerebral ischemia activates the nuclear protein poly (ADP-ribose) polymerase (PARP)
by single DNA strand breaks which leads to energy depletion and cell necrosis. Deletion or …
by single DNA strand breaks which leads to energy depletion and cell necrosis. Deletion or …
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy …
S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - Taylor & Francis
Background Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …
for acute ischemic stroke by suppressing microglial activation and facilitating …
Improved reperfusion and vasculoprotection by the poly (ADP-ribose) polymerase inhibitor PJ34 after stroke and thrombolysis in mice
M El Amki, D Lerouet, M Garraud, F Teng… - Molecular …, 2018 - Springer
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …
[HTML][HTML] Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke
For almost three decades, poly (ADP-ribose) polymerase-1 (PARP-1) has been actively
investigated as a potential therapeutic target for a variety of diseases including diabetes …
investigated as a potential therapeutic target for a variety of diseases including diabetes …
Neuroprotective effects of a novel water-soluble poly (ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia
Y Egi, S Matsuura, T Maruyama, M Fujio, S Yuki… - Brain research, 2011 - Elsevier
Cerebral ischemia induces excessive activation of poly (ADP-ribose) polymerase-1 (PARP-
1), leading to neuronal cell death and the development of post-ischemic dysfunction …
1), leading to neuronal cell death and the development of post-ischemic dysfunction …
Early treatment with poly (ADP-ribose) polymerase-1 inhibitor (JPI-289) reduces infarct volume and improves long-term behavior in an animal model of ischemic …
Y Kim, YS Kim, HY Kim, MY Noh, JY Kim, YJ Lee… - Molecular …, 2018 - Springer
In patients with stroke and neurodegenerative diseases, overactivation of poly (ADP-ribose)
polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis …
polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis …
Effects of a newly developed tricyclic PARP‐1 inhibitor, on ischemic stroke
AR Yoo, SH Koh, MY Noh, GW Cho… - Drug Development …, 2010 - Wiley Online Library
Abstract Poly (ADP‐ribose) polymerase (PARP)‐1 plays an important role in the pathogenic
mechanism of ischemic stroke. A number of studies have been undertaken to develop PARP …
mechanism of ischemic stroke. A number of studies have been undertaken to develop PARP …
Reduction of hemorrhagic transformation by PJ34, a poly (ADP-ribose) polymerase inhibitor, after permanent focal cerebral ischemia in mice
M Haddad, V Beray-Berthat, B Coqueran… - European journal of …, 2008 - Elsevier
Hemorrhagic transformation is an aggravating event that occurs in 15 to 43% of patients
suffering from ischemic stroke. This phenomenon due to blood-brain barrier breakdown …
suffering from ischemic stroke. This phenomenon due to blood-brain barrier breakdown …
Combined therapy with PJ34, a poly (ADP‐ribose) polymerase inhibitor, reduces tissue plasminogen activator‐induced hemorrhagic transformations in cerebral …
M Haddad, V Beray‐Berthat… - Fundamental & …, 2013 - Wiley Online Library
Recombinant tissue‐type plasminogen activator (rt‐PA) is presently the only
pharmacological treatment approved for thrombolysis in patients suffering from ischemic …
pharmacological treatment approved for thrombolysis in patients suffering from ischemic …
相关搜索
- adp ribose polymerase inhibitor
- adp ribose cerebral ischemia
- potent poly p2y12 antagonism
- polymerase inhibitor p2y12 antagonism
- potent poly polymerase inhibitor
- antiplatelet effect p2y12 antagonism
- antiplatelet effect polymerase inhibitor
- adp ribose p2y12 antagonism
- potent poly antiplatelet effect
- potent poly adp ribose
- adp ribose antiplatelet effect
- adp ribose parp 1
- protective effects potent inhibitor
- polymerase inhibitor cerebral ischemia
- polymerase parp protective effects
- polymerase inhibitor tissue plasminogen